Coccidioides-Antibody Testing: Introduction, Clinical Significance

Introduction

Table of Contents

For diagnosing coccidioidomycosis (Valley Fever), AI-assisted Coccidioides antibody testing uses enzyme immunoassays (EIA) and immunodiffusion (ID) or complement fixation (CF) tests to detect antibodies against the fungus Coccidioides immitis.

Coccidioidomycosis is a fungal infection caused by Coccidioides immitis.
Antibody tests help diagnose and monitor infections caused by this fungus.
These tests detect the presence of antibodies (IgG and IgM) in the blood that the body produces in response to the infection.

Enzyme Immunoassay (EIA): A screening test that detects antibodies against Coccidioides antigens.
Immunodiffusion (ID): A confirmatory test that detects antibodies to specific Coccidioides antigens.
Complement Fixation (CF): Another confirmatory test that measures the concentration of antibodies in the blood.

EIA: Detects the presence of antibodies in a sample by using an enzyme-linked antibody that binds to the target antigen.
ID: Detects antibodies by observing the formation of a visible band where the antibodies and antigens interact.
CF: Detects antibodies by observing whether the antibodies in the sample prevent complement from lysing red blood cells.

Positive Results: Indicate the presence of antibodies and suggest a current or past infection.
Negative Results: Indicate the absence of antibodies.
Equivocal Results: May require further testing or repeat testing.

AI can be used to analyze test results, identify patterns, and potentially improve diagnostic accuracy.
For example, a study published in PubMed developed a rapid lateral flow assay (LFA) for the detection of anti-coccidioidal antibodies, which could be used with AI for faster and more efficient diagnosis.

In endemic areas, a diagnosis of coccidioidomycosis may be suggested based on clinical findings, but confirmation requires laboratory testing.
The coccidioidin skin test is an indicator of exposure to the fungus.
Antibodies to the TP antigen are typically detectable within 4 weeks of primary onset of infection but are rarely detected 6 months after infection.
Once a diagnosis of coccidioidomycosis has been established, the CF antibody test should be used for ongoing management since none of the other tests have been shown to have prognostic value.